



**Together expands its international presence:
The Israeli cannabis company is the first in the country
to eye export and distribution of medical cannabis
products in Brazil, one of the world's largest countries**

**Together will produce oils designed for sale in accordance with regulation
in Brazil, with a focus on CBD enriched products for treating epilepsy**

Ashkelon. August 3, 2020 – Together (TASE: TGDR), which specializes in cultivating and manufacturing of medical cannabis products, announced the expansion of its international activities to Brazil, where it will be the first Israeli medical cannabis public company to operate in this huge market.

The company has signed a Memorandum of Understanding (MoU) to market and distribute medical cannabis products in the Brazilian market, through a partner who will be responsible for receiving the required approvals to import medical cannabis products for sale in the country. CBD oils are sold in Brazil in small 30 milligram bottles for the equivalent price of NIS 1,800, therefore the company plans to focus on selling enriched CBD oils for treating epilepsy.

Together CEO Nissim Bracha: "The Brazilian market is an enormous market with a population that is 20 times larger than Israel so that we see major economic potential in Brazil to generate revenue from medical cannabis oils, while expanding our international presence. We are currently completing the construction of a factory for manufacturing medical cannabis products in Ashkelon next to the farm. We will allocate a special area for producing GMP products, adapted to the regulation required in Brazil, which permits imports but does not allow local cultivation, thus opening up a big business opportunity for us. The agreement in Brazil is an additional source of income for Together. It will operate in parallel to the Israeli farm and sales operations of quality medical cannabis products to pharmacies and patients as well as with activities on the farm in Uganda, from where we will continue this year to import large amounts of medical cannabis products to Israel."

Together recently reported that it had received an additional permit to import 600 kilograms of GACP standard medical cannabis products from Uganda, where the company operates a 7.5 acre farm, which has been in full commercial operations of planting, cultivating, harvesting, and packing cannabis inflorescences for medical use. The cost of the produce from Uganda allows the company to maintain very high profit margins.



Together has an exclusive agreement with a pharmacy in Tel Aviv to distribute products as well as agreements with 12 pharmacies around Israel. After processing the consignment of the final products from Uganda, Together will market the produce with the aim of increasing its market share. Alongside production from Uganda, Together continues to plant, cultivate, harvest and pack on an ongoing basis at its five acre farm in Israel.

Together's facilities include a farm in Israel, which complies with the IMC-GAP and GACP standards and it is completing construction of an IMC-GMP standard factory and it plans obtaining the EU-GMP standard in order to also export products bearing the standard to Europe.

Regulation in Brazil

To the best of the company's knowledge, Brazil has approved the setting up of the medical cannabis sector as part of which patients can buy cannabis pructs in pharmacies, and for the first time use cannabis legally with a medical prescription. However, the proposal to also build cultivation and production facilities in the country has been rejected, so that most of the cannabis is imported from abroad, without importing the plants' ingredients, only as a finished product or raw material from source.

The company estimates that developing the medical cannabis sector in Brazil can make Brazil into the world's largest market for importing cannabis. The sector is working on a 'pilot' format for three years, after which the situation will be reviewed. Marketing of cannabis-based cosmetics and food products will not be allowed.

To the best of the company's knowledge, Brazil has a population of more than 200 million. On average, two years after a country approves medical cannabis, one percent of the population have used a prescription. In other words, in the case of Brazil, it can be assumed that within two years there will be two million medical cannabis users. To the best of the company's knowledge, there are 1.9 million epilepsy sufferers in Brazil for whom CBD treatment from medical cannabis would serve as a treatment for the illness.